CSI Market
Sign In | Register

Aslan Pharmaceuticals Limited (ASLN) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ASLN Annual Balance Sheets →
Examining balance sheet movements between Aslan Pharmaceuticals Limited and Dec 31 2022 reveals how Dec 31 2023 adjusts its asset composition and liability profile.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
0 0 0 (Dec 31 2022)
Assets
Cash And Cash Equivalents21.25
Cash & Short-term Investments21.00
Accounts receivable0.00
Other Current Assets2.88
Total Current Assets24.13
Equipment/Property/Plant Net0.03
Intangible Assets0.00
Other Assets, Noncurrent0.47
Total Assets24.63
Liabilities
Short-term Debt24.80
Total Current Liabilities13.11
Total Long-term Debt0.00
Other liabilities, Noncurrent13.11
Total Liabilities37.91
Stockholders' Equity
Other Equity-13.29
Common Stockholder's Equity-13.29
Total Stockholder's Equity-13.29
Liabilities & Stockholder's Equity24.63
4 historic quarters locked

Sign in to unlock the full Aslan Pharmaceuticals Limited balance sheet history.

Sign In Create Free Account

About Aslan Pharmaceuticals Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-043860

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.